Ann: Anagrelide Cancer Patent For Japan, page-9

kippax: Of course, this is good news. However, this PATENT will ONLY ever present real commercial VALUE once the Anagrelide research programme has reached at least good success in a Phase II research study - a comprehensive and expensive and time-consuming undertaking ahead for SUDA company!! How on earth will they FINANCE that on their own??
Another CR at current very low sp will ONLY bring about some very short-term survival funding - IMHO, of course!
I see only two possible solutions:

A) Sell SUDA to another company that has the necessary funds (money) and that is already involved with Cancer Research or
B) Get a kind of JV partner to go forward with Anagrelide specifically (here also best to go with another company already involved in Cancer)

Alternatively, there is always the other 'opportunity' to let the company go bankrupt, of course.

Time will tell as usual.

All the aforementioned purely JIMHO. And as so often, I could be wrong. COMMENTS most welcome as usual.

wasa